Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

"Nexalin Gen-2 Neurostimulation Device"

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales of its second generation (Gen-2), 15 milliamp (mA) neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin’s neurostimulation device for the treatment of patients with substance abuse disorder (SUD).

The new clinic opened and commenced treatment of patients with Nexalin’s Gen-2 neurostimulation device following a successful evaluation and inspection of the facility by the Sultanate of Oman’s Ministry of Health, which ensures strict quality standards and adherence to established and robust guidelines and regulations. As previously announced, Nexalin was recently granted regulatory approval for its Gen-2, 15 milliamp (mA) neurostimulation device by the Sultanate of Oman’s Ministry of Health.

Mark White, CEO of Nexalin Technology, stated, “We are pleased to commence commercial sales of our Gen-2 neurostimulation device in Oman following regulatory approval by the Sultanate of Oman’s Ministry of Health. Importantly, the new center is exclusively focused on providing comprehensive treatment of patients with SUD, utilizing Nexalin’s Gen-2 neurostimulation device, with plans to expand into the treatment of other mental health disorders. We believe the selection of Nexalin’s technology as the cornerstone of a new health center is a significant validation of our new and drug-free therapy in generating enhanced patient therapeutic responses without adverse side effects.”

“I am extremely proud of the efforts by our executives and staff, who supported the new health center’s leadership in obtaining Ministry of Health certification and commissioning operations in record time. We believe this new health center will serve as a model across the Middle East and around the world as we work toward our goal of transforming the paradigm of mental health treatment.”

“We are especially grateful for the support of the National Committee for Narcotics and Psychotropics Substances (NCNPS) and the officials who joined us for the opening ceremonies. We appreciate their faith in our mission to combat addiction, as well as the global mental health epidemic, while reducing the growing dependence on pharmaceuticals that are often ineffective and may have undesirable side effects.”

Author

+ posts

Leave a Reply

Your email address will not be published. Required fields are marked *